Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).
Mayer believes it is not yet known who benefits from these targeting agents. There is phase II data for CDK4/6 inhibition in the first-line setting, which is encouraging because the preliminary results showed an improvement in progression-free survival, adds Mayer.
However, the phase III data does not yet have complete mature results, so it is difficult to determine whether or not the combination will yield an overall survival advantage.
Ingrid A. Mayer, MD, MSCI, co-leader and clinical director, Breast Cancer Research Program, chair, Data and Safety Monitoring Committee, associate professor of medicine (hematology/oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More